Biotron Ltd
BIT
Company Profile
Business description
Biotron Ltd is an Australian biotechnology company focused on the development and commercialization of antiviral therapies and neuroscience-related products. The company reports two operating segments: SedRx, focused on anesthetic and neuroscience products, and Viron, which encompasses antiviral drug development programs. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
Contact
66 Hunter Street
Level 2
SydneyNSW2000
AUST: +61 293003344
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
4
Stocks News & Analysis
stocks
Weight loss drugs not an existential threat to undervalued ASX share
A durable growth story despite GLP-1 headwinds.
stocks
Tesla: valuation is key consideration in merger talks with SpaceX
We see regulatory risk from both the US and Chinese governments.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.20 | 23.40 | -0.26% |
| CAC 40 | 7,847.32 | 64.50 | 0.83% |
| DAX 40 | 25,410.84 | 229.19 | 0.91% |
| Dow JONES (US) | 52,361.58 | 146.42 | 0.28% |
| FTSE 100 | 10,767.33 | 76.97 | 0.72% |
| HKSE | 23,211.81 | 118.44 | 0.51% |
| NASDAQ | 26,169.38 | 214.04 | 0.82% |
| Nikkei 225 | 63,250.10 | 1,060.45 | 1.71% |
| NZX 50 Index | 13,627.66 | 106.27 | -0.77% |
| S&P 500 | 7,676.77 | 53.09 | 0.70% |
| S&P/ASX 200 | 8,783.60 | 26.30 | -0.30% |
| SSE Composite Index | 3,697.52 | 7.04 | 0.19% |